Botling J. et al described changes in Pancreatic Neuroendocrine Tumors (PanNETs) differentiation and proliferation over time, and correlated findings to overall survival. A total of 475 PanNET patients were screened during treatment at Uppsala University Hospital, Sweden. The researchers included 46 patients with 106 tumor samples in their analyses. In a majority of PanNETs, a longitudinal increase in Ki-67 index and an increase in tumor grade were noted. Further study was proposed as essential biomarkers in PanNET to increase the Ki-67 index and high-grade progression.
Little is known about how Pancreatic Neuroendocrine Tumors (PanNETs) evolve over time and if changes towards a more aggressive biology correlates with prognosis. The purpose of this study was to characterize changes PanNET differentiation and proliferation over time, and to correlate findings to overall survival (OS).
Patients and methods:
In this retrospective cohort study we screened 475 PanNET patients treated at Uppsala University Hospital, Sweden. Sporadic patients with baseline and follow-up tumor samples were included. Pathology reports and available tissue sections were re–evaluated with regard to tumor histopathology and Ki-67 index.
Forty-six patients with 106 tumor samples (56 available for pathology re–evaluation) were included. Median Ki-67 index at diagnosis was 7% (range 1–38%), grade 1 n=8, grade 2 n=36, and grade 3 n=2. The median change in Ki-67 index (absolute value; follow-up - baseline) was +14% (range -11 to +80%). Increase in tumor grade occurred in 28 patients (63.6%), the majority from grade 1/2 to grade 3 (n=24, 54.5%). The patients with a high-grade progression had a median OS of 50.2 months compared to 115.1 months in patients without such progression (HR 3.89, 95% CI 1.91–7.94, P<0.001).
A longitudinal increase in Ki-67 index and increase in tumor grade were observed in a majority of PanNETs included in this study. We propose that increase in Ki-67 index and high-grade progression should be investigated further as important biomarkers in PanNET.